Dithiolethiones for cancer chemoprevention: where do we stand?
Dithiolethiones for cancer chemoprevention: where do we stand?
复制标题
DOI：
10.1158/1535-7163.mct-08-0625
复制
发表时间：
2008-11
影响因子：
5.7
通讯作者：
Munday R
中科院分区：
文献类型：
--
作者：
Zhang Y;Munday R
Dithiolethiones are a well-known class of cancer chemopreventive agents, whose key mechanism of action involves activation of Nrf2 signaling and induction of Phase 2 enzymes. In the past, attention has been focused mainly on 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz), which showed ability as a wide-spectrum inhibitor of chemical carcinogenesis in preclinical models. However, clinical trials of oltipraz have shown questionable efficacy and, at the high doses employed in such studies, significant side effects were observed. Dithiolethiones that are markedly more effective and potent than oltipraz in both induction of Phase 2 enzymes and inhibition of chemical carcinogenesis in preclinical studies have been identified, and these compounds have shown pronounced organ specificity in vivo. Further investigation of these compounds may lead to development of effective and safe agents for cancer prevention in humans.
